ArticleJournal of medical biochemistry2026
The combination of cyclin D1 and MRI radiomics parameters improves breast cancer diagnosis and NACT efficacy assessment.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The purpose of this study is to evaluate the combined diagnostic performance of Cyclin D1 and magnetic resonance imaging (MRI) parameters in breast cancer (BC), while also assessing their ability to forecast treatment response to neoadjuvant chemotherapy (NACT), so as to provide evidence for individualized treatment strategies. Methods: A total of 154 BC patients and 148 healthy women matched with BC patients in age and BMI were enrolled in this study. Peripheral blood Cyclin D1 quantification utilized enzyme-linked immunosorbent assay (ELISA), and CA15-3 and CA27.29 (both tumor markers) measurements were made using automated electrochemiluminescence immunoassay. Magnetic resonance imaging (MRI) was conducted to obtain dynamic contrast-enhanced scans, from which radiomics parameters (PSIER, TSICS, ADC) were derived. Diagnostic accuracy for BC and predictive value for chemotherapy response were evaluated through correlation analysis (Pearson), receiver operating characteristic (ROC) curves, and multivariate regression modeling. Results: Cyclin D1 levels were elevated in BC patients compared to healthy controls and showed a positive connection with CA15-3 and CA27.29 (P< 0.05). The diagnostic performance of Cyclin D1 alone yielded an AUC of 0.830, whereas a combined model incorporating MRI parameters (PSIER, TSICS, and ADC) significantly improved discrimination (AUC = 0.935, sensitivity 86.36%, specificity 87.84%). During NACT, Cyclin D1 levels declined dynamically. A predictive model integrating Cyclin D1 and imaging biomarkers achieved an AUC of 0.775 for identifying poor NACT responders (sensitivity 88.37%, specificity 56.76%). Conclusions: The combination of Cyclin D1 and MRI parameters enhances both BC diagnostic accuracy and NACT efficacy prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.